Clinical trials: Depression Diagnosis
Depressive Disorder, Cancer
Carcinogenicity Study of Bupropion
There is a lack of toxicology data on one bupropion metabolite, and limited literature examining bupropion use and cancer risk. This study evaluates the association between bupropion exposure and the development of cancer of the…
- Trial name
- NCT01077596
- Testing
- Regular bupropion use, Regular SSRI (Selective serotonin reuptake inhibitors) use, Regular TCA (Tricyclic antidepressants) use
- Volunteers
- 50,430 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
The purpose of this study is to assess the efficacy of a Deep Shaped-Field repetitive transcranial magnetic stimulation (DSF-rTMS) system in the treatment of depression.
- Trial name
- NCT01431001
- Testing
- Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
- Where
- 4 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Cervel Neurotech, Inc.
Insomnia
Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro
To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and escitalopram at 2 months.
- Trial name
- NCT00296179
- Testing
- zolpidem tartrate
- Volunteers
- 372 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder (MDD) is a severe and common psychiatric disorder. Although MDD primarily involves mood disturbances, patients also usually present alterations in cognitive function (attention, memory, executive…
- Trial name
- FOCUS (NCT01422213)
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 598 people
- Sponsor
- H. Lundbeck A/S
Depressive Symptoms
EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision)…
- Trial name
- SAMEUP (NCT03932474)
- Testing
- SAMEUp
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Nutrilinea srl
Major Depressive Disorder (MDD)
A Study of HS-10353 in Adult Participants With Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of continuous oral administration of HS-10353 in Chinese adults with depression.HS-10353 is a new generation of…
- Trial name
- NCT05938179
- Testing
- HS-10353 30mg oral capsules, HS-10353 50mg oral capsules
- Volunteers
- 144 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Depressive Disorder, Major
A Study of GW856553X For the Treatment of Depression
GW856553 is a novel compound, currently in development for the treatment of Major Depressive Disorder (MDD), and other indications.
- Trial name
- NCT00569062
- Testing
- GW856553X
- Where
- 15 sites in Estonia, India and 1 more
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Depressive Disorder and Anxiety Disorders
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses.
- Trial name
- NCT00435695
- Testing
- GSK163090
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Postpartum
IMI PROTECT(WP2): Antidepressants & Fractures
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1.
- Trial name
- NCT01587729
- Testing
- Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Treatment Resistant Depression
Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI
Healthy controls (HC) will be studied once to provide data needed to validate the virtual neuro-navigation system. All subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in…
- Trial name
- NCT05598931
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Soterix Medical
Depression, Bipolar
Olanzapine Treatment of Patients With Bipolar I Disorder
The purpose of this study is to assess whether olanzapine is superior to placebo in patients with bipolar depression.
- Trial name
- NCT00510146
- Testing
- Olanzapine
- Where
- 16 sites in China, Japan and 1 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)
- Trial name
- NCT00048204
- Testing
- GW597599B, paroxetine
- Volunteers
- 372 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of…
- Trial name
- NCT00811252
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
MDD
Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD
This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and…
- Trial name
- NCT06828887
- Testing
- LV232 40mg, LV232 60mg, Escitalopram
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Vigonvita Life Sciences
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi
Major Depressive Disorder
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
- Trial name
- NCT03193398
- Testing
- BTRX-246040 oral capsule(s)
- Where
- 8 sites in United States
- Volunteers
- 104 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Depressive Disorder, Major
SA4503 8-Week Study in Major Depressive Disorder (MDD)
The purpose of this study is to determine the efficacy of SA4503 compared to placebo in the treatment of subjects with major depressive disorder (MDD).
- Trial name
- NCT00551109
- Testing
- SA4503 Low, SA4503 High
- Where
- 5 sites in Finland
- Volunteers
- 150 people
- Sponsor
- M's Science Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.